All In Biotech

Drug Trial Radar · NCT06089330

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

A Randomized, Controlled, Open-label Phase Ⅱ Study of The Safety, Tolerability and Efficacy of JMT101 and Irinotecan Combined With SG001 in Patients With Metastatic Colorectal Cancer (mCRC)

Last checked: Nov 19, 2026Latest source record: Oct 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

102

Planned (sponsor's estimate)

Start

Jan 2024

Primary completion

Jul 2024

Study completion Dec 2024

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Oct 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer (mCRC).

Conditions

  • Metastatic Colorectal Cancer (mCRC)

Interventions

  • JMT101Drug

    JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

  • SG001Drug

    240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

  • IrinotecanDrug

    180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).

  • Regorafenib (Stivarga)Drug

    160 mg, taken orally once daily for the first 21 days of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: After1 cycle of treatment of the safety run-in phase patients (each cycle is 28 days)
  2. Overall response rate (ORR)Time frame: Up to approximately 2 years
  3. Incidence and severity of adverse events (AE) and serious adverse events (SAE)Time frame: Up to approximately 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.